Which Fund Has The Most To Gain From Biogen Idec?

The S&P medical sector is still leaving the competition in the dust, with a year-to-date gain of 13.58 percent, using the SPDR Health Care ETF (ETF: XLV) as a proxy.Third-quarter consensus estimates for health care leaders look promising. In addition to Gilead Sciences (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB) is another widely held, institutional quality large cap poised for a solid quarterly earnings increase. Analysts see quarterly earnings rising to $3.46 per share, from $2.35 per share in the year-earlier quarter.The company reports earnings on October 22, before the opening bell. The number of domestic mutual funds and hedge funds owning Biogen has been on the rise, with 2,014 holding shares at the end of the third quarter. The fund owning the most Biogen shares is the Vanguard Primecap fund (MUTF: VPMCX), which holds 4.22 percent of shares, or a whopping 7.23 percent of fund assets. This actively managed fund has a strategy of identifying stocks that have growth potential, but are trading at a value at the time of purchase. Health care is the No. 2 sector represented in the Primecap fund, behind technology. The fund tends to hold stocks for a long time, which keeps trading costs down. It has a net expense ratio of 0.45 percent, lower than many actively managed funds. Its Net Asset Value is $98.97, and it has a year-to-date gain of 6.95 percent. The fund's total assets are $ 44.3 billion. The top four holdings within the fund hail from the health care sector: Biogen Idec, Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Co. (NYSE: LLY), and Roche Holding AG (OTC: RHHBY).Significant holdings from other sectors include FedEx Corp.(NYSE: FDX), Adobe Systems Inc. (NASDAQ: ADBE), Texas Instruments Inc. (NASDAQ: TXN), and Microsoft Corp. (NASDAQ: MSFT).